Gastrointestinal stromal tumour

The PBS subsidises imatinib, ripretinib and sunitinib for patients with gastrointestinal stromal tumour.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with imatinib, ripretinib and sunitinib under the National Health Act 1953, section 85 for patients with gastrointestinal stromal tumour (GIST).

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing imatinib, ripretinib and sunitinib.

Authority applications

Applying for initial treatment

Applications for initial PBS subsidised imatinib and ripretinib to treat resected primary GIST and high risk of recurrence, or metastatic or unresectable malignant GIST can be made either:

Apply for initial authority approval to prescribe PBS subsidised sunitinib to treat metastatic or unresectable malignant GIST in writing and either:

All applications must include the completed:

Continuing

Continuing PBS subsidised imatinib to treat resected primary GIST with high risk of recurrence, or metastatic or unresectable malignant GIST is Authority Required (Streamlined). It doesn’t need authority approval from us for listed quantities and repeats.

Continuing PBS subsidised ripretinib to treat metastatic or unresectable malignant GIST can be made either:

Continuing PBS subsidised sunitinib to treat metastatic or unresectable malignant GIST is Authority Required (Streamlined). It doesn’t need authority approval from us for listed quantities and repeats.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 10 December 2021